Fundraising FoxElucid Bioimaging
Boston, US · 5 known investors
Find your way into Elucid Bioimaging
Each arrow is one introduction. Sign up to fill in the first one.
Ask Eric Reiter to introduce you to Kelly Huang
You →Eric · together at L-Nutra →Kelly
Sign up to find every way you can get introduced to Elucid Bioimaging
- Your email: who you already know at Elucid Bioimaging, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Elucid Bioimaging team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Elucid develops artificial intelligence technology that analyzes CT images to identify hidden features of cardiovascular risk and guide personalized treatment of coronary artery disease. The platform enables physicians to create detailed disease maps and deliver personalized care based on individual patient anatomy.
Founders & leadership
Board
Investors · 5
How we know: Angel Physicians Fund's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$225.4M disclosed across 4 rounds · 2023–2026
▶$36.5MraisedOct 2025 · 9 investors · BiotechnologyRule 506(b)
- Evan MelroseDirector
- Michael LeshDirector
- Blake RichardsExecutive Officer
- Richard KuntzDirector
- Rajesh PandaDirector
- Kelly HuangExecutive Officer, Director
- Shamiram FeinglassDirector
- Scott HuennekensDirector
- Offering amount
- $80M
- Amount sold
- $36.5M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$79MraisedNov 2023 · 13 investors · BiotechnologyRule 506(b)
- Robert BraunDirector
- Scott HuennekensExecutive Officer, Director
- Michael LeshDirector
- Blake RichardsExecutive Officer, Director
- Evan MelroseDirector
- Offering amount
- $79M
- Amount sold
- $79M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Elucid Bioimaging do?
- Elucid develops artificial intelligence technology that analyzes CT images to identify hidden features of cardiovascular risk and guide personalized treatment of coronary artery disease. The platform enables physicians to create detailed disease maps and deliver personalized care based on individual patient anatomy.
- Who are Elucid Bioimaging's investors?
- Elucid Bioimaging's investors include Angel Physicians Fund, Aphelion Capital, BlueStone Venture Partners, IAG Capital Partners, MedTex Ventures LLC.
- How much funding has Elucid Bioimaging raised?
- Elucid Bioimaging has disclosed $225.4M raised across 4 rounds.
- Where is Elucid Bioimaging headquartered?
- Elucid Bioimaging is headquartered in Boston, US.